Publications

The biotech industry is evolving rapidly, with emerging companies leading the charge in clinical development. As outs...

Early-phase oncology combination trials often assume the optimal dose is already included in the dosing gri...

As the pharmaceutical landscape evolves, traditional clinical trial designs are increasingly complemented by innovati...

Discover how Bayesian statistics can enhance clinical trial efficiency and improve decision-making. Our latest white ...

Discover how Real-World Evidence (RWE) is revolutionizing drug development and clinical decision-making in our latest...

As oncology drug development continues to evolve, the FDA’s Project Optimus is reshaping how clinical trials ap...

EU HTA regulations are changing the way we conduct HTA submissions with EU regulators. Prior to the introduction of t...

The way health technology assessments (HTAs) are conducted in Europe is undergoing a significanttransformation. Start...

Navigating Clinical Monitoring Challenges For over a decade, Phastar has been at the forefront of the clinical monito...

Author: Professor Deborah Ashby Interim Dean of the Faculty of Medicine, Imperial College London About the lecture&nb...

Authors: Giles Partington, Lindsay Govan, Paddy O’Hara, Emily Foreman, and Jennifer Visser-Rogers | Phastar Abstract ...

Author: Stephen Corson | Phastar We are delighted to have made available two slideshow presentations given by Phastar...